Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tolterodine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Tolterodine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-022121-15 Sponsor Protocol Number: 4618-008 Start Date*: 2011-04-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 52-week Extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) DK (Completed) AT (Completed) NO (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002533-18 Sponsor Protocol Number: 4618-008-10 Start Date*: 2012-06-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: 52 Week Extension: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002640-97 Sponsor Protocol Number: A6121128 Start Date*: 2004-10-27
    Sponsor Name:Pfizer
    Full Title: Time to onset of action of tolterodine using force fill cystometry in SPINAL CORD INJURY PATIENTS WITH neurogenic detrusor overactivity.
    Medical condition: Neurogenic detrusor overactivity in patients with spinal cord injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2005-004249-33 Sponsor Protocol Number: A8881001 Start Date*: 2005-12-14
    Sponsor Name:Pfizer Limited
    Full Title: A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination ...
    Medical condition: Overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10059617 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) SK (Completed) SE (Completed) CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001068-36 Sponsor Protocol Number: R03465 Start Date*: 2014-10-22
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)
    Medical condition: Idiopathic Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004126-24 Sponsor Protocol Number: DRI6271 Start Date*: 2007-12-12
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overac...
    Medical condition: Overactive bladder including urge urinary incontinence
    Disease: Version SOC Term Classification Code Term Level
    10.0 10059617 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) PT (Completed) FR (Completed) NL (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002143-27 Sponsor Protocol Number: 1208.15 Start Date*: 2005-02-15
    Sponsor Name:Boehringer Ingelheim Austria GmbH
    Full Title: A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (...
    Medical condition: Urge Urinary Incontinence (UUI)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DK (Prematurely Ended) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006451-39 Sponsor Protocol Number: A0221046 Start Date*: 2008-02-20
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) LT (Completed) ES (Completed) HU (Completed) GR (Completed) EE (Completed) LV (Completed) SK (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-024179-18 Sponsor Protocol Number: A0221094 Start Date*: 2011-05-31
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) DE (Completed) CZ (Completed) FI (Completed) GR (Completed) BG (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006070-22 Sponsor Protocol Number: A0221007 Start Date*: 2007-03-16
    Sponsor Name:Pfizer Inc
    Full Title: A 12-WEEK, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTS OF FESOTERODINE ON TREATMENT SATISFACTION AND SYMPTOM RELIEF IN OVERACTIVE BLADDER PATIENTS
    Medical condition: Overactive bladder (OAB) is a symptom complex defined by the International Continence Society (ICS) as the symptoms of urgency, with or without urgency incontinence, usually with frequency and noct...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006935-38 Sponsor Protocol Number: A0221008 Start Date*: 2007-04-16
    Sponsor Name:Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) HU (Completed) DK (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004854-26 Sponsor Protocol Number: ELB245201-06 Start Date*: 2007-02-16
    Sponsor Name:elbion AG
    Full Title: A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg flupirtine (ELB245) given once daily for 12 ...
    Medical condition: Incontinent Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002256-17 Sponsor Protocol Number: 178-CL-044 Start Date*: 2006-01-19
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON)
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) ES (Completed) SE (Completed) BE (Completed) HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-006201-12 Sponsor Protocol Number: 003 Start Date*: 2007-01-10
    Sponsor Name:MERCK SHARP DOHME
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder
    Medical condition: overactove bladder
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046494 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006538-33 Sponsor Protocol Number: ONO-8539POE004 Start Date*: 2009-03-23
    Sponsor Name:Ono Pharmaceutical Co. Ltd.
    Full Title: A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BL...
    Medical condition: Overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-004452-13 Sponsor Protocol Number: A6121127 Start Date*: 2005-12-16
    Sponsor Name:Pfizer Inc.
    Full Title: A Randomized, Double Blind, Placebo Controlled Detrol La "Add-On" To Alpha-Blocker Study in men with persistent Overactive Bladder symptoms of urinary frequency and urgency with/without urgency inc...
    Medical condition: Overactive Bladder in Men
    Disease: Version SOC Term Classification Code Term Level
    8.0 10020853 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed) ES (Completed) DK (Completed) GB (Completed) SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001116-31 Sponsor Protocol Number: ESCLIN-002/04 Start Date*: 2004-11-03
    Sponsor Name:Laboratorios Dr. Esteve S.A.
    Full Title: Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (...
    Medical condition: Urge Urinary Incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005606-23 Sponsor Protocol Number: 0594-003 Start Date*: 2006-03-24
    Sponsor Name:Merck Sharp and Dohme de España
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder Estudio multicéntrico, doble ciego, aleato...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.0 10059617 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003294-33 Sponsor Protocol Number: RVT-901-3004 Start Date*: 2018-07-06
    Sponsor Name:Urovant Sciences GmbH
    Full Title: An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients with Symptoms o...
    Medical condition: Adult men and women with either: * OAB Wet * OAB Dry
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003293-14 Sponsor Protocol Number: RVT-901-3003 Start Date*: 2018-07-06
    Sponsor Name:Urovant Sciences GmbH
    Full Title: An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overa...
    Medical condition: Adult men and women with either: •OAB Wet • OAB Dry
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) EE (Completed) BG (Prematurely Ended) LT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:10:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA